Search results
Updates in Managing Elderly Patients With Type 2 Diabetes
Medscape· 5 days agoTeaching Hospital in Saint-Mandé, France, discussed these topics at the Francophone Diabetes Society...
Signs and Symptoms of Diabetes Insipidus
Health via Yahoo News· 5 days agoThis condition should not be confused with diabetes mellitus, which includes type 1 and 2
What’s Healthier, Canola Oil or Olive Oil? The Answer Isn’t as Black and White as You Might Think
Parade via Yahoo News· 5 days agoCells. Extra-virgin olive oil and the gut-brain axis: influence on gut microbiota, mucosal immunity,...
Burkholderia thailandensis Isolated from Infected Wound, Southwest China, 2022
Centers for Disease Control and Prevention· 3 days agoBurkholderia thailandensis Isolated from Infected Wound, Southwest China, 2022
New genes associated with adult-onset obesity - Nature Reviews Endocrinology
Nature· 5 days agoThe factors that determine an individual’s body weight are highly complex and incompletely understood. Currently, >1,000 genes that are associated with body weight have been ...
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate...
Morningstar· 5 days agoAmarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further ...
'Illness To Wellness' and ILBS caution against rising cases of liver disease, stress urgent need to...
Investing.com· 5 days agoNew Delhi, April 24 (IANS) The ‘Illness to Wellness’ initiative, a national campaign aimed at...
Corcept Therapeutics (NASDAQ:CORT) Hits New 12-Month Low at $20.84
ETF DAILY NEWS· 5 days agoCorcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) shares hit a new 52-week low during trading on Monday . The company traded as low as $20.84 and last traded at $22.22, with ...
Corcept Therapeutics (NASDAQ:CORT) Stock Rating Upgraded by StockNews.com
ETF DAILY NEWS· 2 days agoSeveral other research analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday ...